Αρχική World News Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell... World News Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer Από Ogkologos - 25 Οκτωβρίου, 2026 58 0 Facebook Twitter Google+ Pinterest WhatsApp Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR 3 Steps to Making the Right Decisions for You During Cancer:... 8 Φεβρουαρίου, 2024 EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel 26 Αυγούστου, 2025 Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia 22 Ιουνίου, 2018 Mom with Breast Cancer Who Had A Year to Live Goes... 2 Απριλίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Sacituzumab Govitecan Plus Pembrolizumab Demonstrate Encouraging Activity in Patients with mUC... Working Mom with Stage II Breast Cancer Receives Custom Wig Made... Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients... Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms